A Novel Insulin Unit Calculator for the Management of Type 1 Diabetes
| العنوان: | A Novel Insulin Unit Calculator for the Management of Type 1 Diabetes |
|---|---|
| المؤلفون: | Silvia Manfrini, Anna Rita Maurizi, Angelo Lauria, Paolo Pozzilli, Daria Maggi, Andrea Palermo, Elvira Fioriti |
| المصدر: | Diabetes Technology & Therapeutics. 13:425-428 |
| بيانات النشر: | Mary Ann Liebert Inc, 2011. |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Adolescent, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Insulin dose, law.invention, Young Adult, Endocrinology, law, Internal medicine, Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Insulin, Aged, Glycemic, Glycated Hemoglobin, Type 1 diabetes, Computers, business.industry, Gold standard (test), Middle Aged, medicine.disease, Medical Laboratory Technology, Diabetes Mellitus, Type 1, Calculator, Female, business |
| الوصف: | Intensive insulin therapy is the gold standard therapy for type 1 diabetes (T1D) patients. To achieve optimal glycemic control, adjustments of insulin dose at mealtimes must be made taking into account several parameters: blood glucose levels, insulin/carbohydrate ratio, carbohydrate intake, and physical activity. Calsulin (Thorpe Products Ltd., Cambridge, UK) is a new tool for the administration of insulin dose before each meal. The aim of this study was to evaluate the efficacy of Calsulin on metabolic control in T1D patients undergoing intensive insulin therapy.Forty consecutive patients affected by T1D, 18-65 years old, with disease duration of1 year, were randomized to Calsulin or to the control group. Hemoglobin A1c (HbA1c) was evaluated at entry into the study and at 3- and 6-month follow-ups. Paired t test (two tailed) and analysis of variance were used to evaluate differences in HbA1c at 3 and 6 months in the two groups.HbA1c at entry was 7.9 ± 1.0% (SD) in the Calsulin-treated group and 7.8 ± 1.6% (SD) in control patients (P not significant). Data showed a slight improvement in HbA1c levels at 3 months in the Calsulin-treated group (-0.61% vs. -0.14% difference, respectively; P not significant). At the 6-month follow-up, a significant reduction in HbA1c levels was observed in the Calsulin-treated group versus the control group (-0.85% vs. -0.07% difference, respectively; P0.05).Calsulin is an acceptable and practical tool that makes the process of calculating insulin doses easy to use, and, most importantly, it improves metabolic control as shown by a significant reduction of HbA1c levels. |
| تدمد: | 1557-8593 1520-9156 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1527549a8ab31a7a99a3fe74cecdf97aTest https://doi.org/10.1089/dia.2010.0190Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....1527549a8ab31a7a99a3fe74cecdf97a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15578593 15209156 |
|---|